KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Total Non-Current Liabilities (2020 - 2025)

Historic Total Non-Current Liabilities for AbCellera Biologics (ABCL) over the last 6 years, with Q3 2025 value amounting to $323.2 million.

  • AbCellera Biologics' Total Non-Current Liabilities rose 3741.36% to $323.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $323.2 million, marking a year-over-year increase of 3741.36%. This contributed to the annual value of $227.9 million for FY2024, which is 511.8% up from last year.
  • AbCellera Biologics' Total Non-Current Liabilities amounted to $323.2 million in Q3 2025, which was up 3741.36% from $328.0 million recorded in Q2 2025.
  • AbCellera Biologics' Total Non-Current Liabilities' 5-year high stood at $328.0 million during Q2 2025, with a 5-year trough of $83.0 million in Q1 2021.
  • Over the past 5 years, AbCellera Biologics' median Total Non-Current Liabilities value was $216.8 million (recorded in 2023), while the average stood at $207.1 million.
  • In the last 5 years, AbCellera Biologics' Total Non-Current Liabilities skyrocketed by 14065.53% in 2021 and then skyrocketed by 344.58% in 2024.
  • Over the past 5 years, AbCellera Biologics' Total Non-Current Liabilities (Quarter) stood at $172.2 million in 2021, then increased by 9.96% to $189.3 million in 2022, then grew by 14.5% to $216.8 million in 2023, then rose by 5.12% to $227.9 million in 2024, then skyrocketed by 41.82% to $323.2 million in 2025.
  • Its last three reported values are $323.2 million in Q3 2025, $328.0 million for Q2 2025, and $245.8 million during Q1 2025.